By Gina Shaw
Adverse drug events (ADEs) were rare and serious ADEs nonexistent in a retrospective, two-year study of nearly 1,900 home and alternate treatment site infusions of infliximab for patients with autoimmune disorders, presented March 22 by Option Care at the National Home Infusion Association Annual Conference & Exposition. 